Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
  • Resources
    • 2022 Massachusetts Biopharma Funding Report
    • 2022 Industry Snapshot
    • 2022 MA Life Sciences Workforce Analysis Report
    • 2021 State of Diversity, Equity, & Inclusion Report
    • Economic Development
    • Value of Health
    • Biopharma Startup Toolkit
    • Career Center
    • MassBioEd
  • Events
    • Events Calendar
    • Overview of Events
    • Get Involved
  • Membership
    • Member Directory
    • Benefits of Membership
    • Savings and Rewards
    • Member News
    • Become a Member
    • Member Rates
    • Pay Company Dues
  • Savings & Rewards
    • MassBioEdge
  • Conference Center
    • MassBioHub
  • Programs
    • Workforce Training Center at Southline Boston
    • State of Possible 2025 Report
    • Diversity, Equity, and Inclusion
    • Policy & Advocacy
    • Partnering Week 2022
    • Partnering Opportunities
    • MassBioDrive
    • Digital Health
    • BioReady Communities
  • About Us
    • About Us
    • News & Thought Leadership
    • Sponsorship Opportunities
    • Staff
    • Board of Directors
    • FAQs
    • Contact Us
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
Open search form

Member Directory

Click to Open Main Menu

Agenus

Life Sciences | Drug Development
Lexington, MA 781-674-4400 Website https://twitter.com/agenus_bio?lang=en LinkedIn Facebook

Overview

Headquartered in Greater Boston in Lexington, Massachusetts, Agenus is a biotechnology company working in immuno-oncology. Immuno-oncology is a field that harnesses the power of the immune system to control or cure cancer. Through its research centers located in Lexington, Massachusetts, Berkeley, California and Cambridge, UK, Agenus is developing a range of immunotherapies, including checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and vaccine adjuvants. CPM development is a particularly fast-moving field where early products produced unprecedented clinical benefits for patients. Agenus’ checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company’s proprietary discovery engine Retrocyte Display® generates fully human therapeutic antibody drug candidates.

Founded in 1994, Agenus platforms are extensively partnered with GlaxoSmithKline, Janssen and Merck. Among Agenus and its partners, more than 20 programs are in clinical development.

At Agenus, we are dedicated to the development of life-changing medicines. Our employees solve complex problems through a culture of innovation, cross-functional teamwork, and commitment to our purpose. We are looking for people who are passionate about our mission and excited by the challenge of working as partners in a rapidly changing landscape.

Company News

News

New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks

Sep 10, 2021

Posted by Agenus

News

Agenus to Participate in September Investor Conferences

Sep 09, 2021

Posted by Agenus

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • Contact
  • Privacy Policy
  • Fulfillment Policy
  • © 2023 All Rights Reserved